医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MMS Director Appointed to the Pharmacovigilance Council for the Indian Society of Clinical Research

2021年08月04日 PM10:01
このエントリーをはてなブックマークに追加


 

BANGALORE, India

MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today that Arunima Sen, MD, Director of Pharmacovigilance and Medical Writing (India), has been appointed to the Indian Society of Clinical Research’s Pharmacovigilance Council.

The Indian Society of Clinical Research (ISCR) brings together those engaged in clinical research activities in India to build awareness of clinical research as a specialty, maintain the highest standards of quality and ethics, and build its growth in the country. Comprised of multinational Indian Pharma and CROs, doctors, site staff, ethics committee members, and clinical researchers, the ISCR aims to provide a forum exchanging information and learning and boasts 42 accredited member organizations and over 620 individual life members.

The ISCR Pharmacovigilance Council aims to:

  • Emphasize the importance of pharmacovigilance in every phase of the pharmaceutical industry
  • Extend support to and collaborate with regulators and other stakeholders to align practices
  • Develop high-quality training materials to instill a culture of reporting in clinical research

“I would like to personally congratulate Arunima for being selected to be part of this esteemed council,” said Michelle Gayari, Executive Vice President, Global Operational Excellence and Innovation, MMS. “This appointment underscores the excellence and strength of our continued leadership in pharmacovigilance and drug safety within the pharmaceutical industry.”

With more than 15 years of experience, Dr. Sen leads colleagues in India to provide comprehensive solutions to meet the pharmacovigilance and drug safety needs of the pharmaceutical industry today. An efficient, adaptable model enables increased productivity, enhances safety monitoring external reporting, and offers Sponsors more time to focus on strategy rather than day-to-day processing activities.

“I am proud to represent MMS and our industry as a whole in this way,” said Dr. Arunima Sen. “Since inception, MMS has been focused on improving the lives of people worldwide, and I believe that this appointment will allow me to pursue that mission at an even greater level.”

Learn more about our pharmacovigilance and drug safety expertise at MMS: https://www.mmsholdings.com/drug-safety-and-pharmacovigilance/

ABOUT MMS

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the last three consecutive years.

For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005063/en/

CONTACT

Lisa James

media@mmsholdings.com

+1 734 738 5062

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
  • Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-2
  • Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
  • Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands
  • KiOmed Pharma and Hansoh Pharma Announce License Agreement for KiOmedinevsOne in China’s Mainland, Macau and Taiwan